腹腔灌注联合静脉化疗治疗晚期卵巢癌疗效观察  被引量:20

Clinical Effect of Intraperitoneal and Intravenous Chemotherapy for Advanced Ovarian Cancer

在线阅读下载全文

作  者:谭文福[1] 张帆[2] 

机构地区:[1]湖北省妇幼保健院妇Ⅱ科,湖北武汉430070 [2]武汉大学中南医院妇瘤科,湖北武汉430071

出  处:《武汉大学学报(医学版)》2015年第1期66-68,128,共4页Medical Journal of Wuhan University

摘  要:目的:探讨顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌患者的疗效和不良反应。方法:选取晚期卵巢癌患者(Ⅲ-Ⅳ期)70例为研究对象,将患者随机分为顺铂联合多西他赛静脉化疗36例(对照组),以及顺铂腹腔灌注联合多西他赛静脉化疗34例(观察组)。对比分析两组化疗效果以及化疗不良反应。结果:观察组患者总有效率为76.47%,对照组总有效率为50.00%,两组比较差异有统计学意义(P<0.05)。观察组不良反应率为47.06%,毒副反应级别主要为Ⅰ-Ⅱ级。观察组与对照组相比,差异有统计学意义(P<0.05)。各组患者5年生存率无统计学意义(P>0.05);而观察组患者3年生存率为55.88%,显著高于对照组,差异有统计学意义(P<0.05)。观察组平均中位生存时间显著优于对照组,差异有统计学意义(P<0.05)。结论:顺铂腹腔灌注联合多西他赛静脉化疗治疗晚期卵巢癌,较顺铂联合多西他赛静脉化疗疗效好,化疗毒副反应小。Objective:To study the response and toxicities of cisplatin(DDP)intraperitoneal and docetaxel intravenous chemotherapy for advanced ovarian cancer.Methods:Seventy patients with advanced stage ovarian cancer(stageⅢ/Ⅳ)were recruited in the study.The patients were randomly received cisplatin and docetaxel intravenous chemotherapy(control group),or intraperitoneal cisplatin with docetaxel intravenous chemotherapy(trial group).Results:The total effective rate of patients of trial group was 76.47%,which was higher than that of control group(50%)(P〉0.05).Trial group also showed lower adverse response rate(47.06%),lower toxicity levels(Ⅰ-Ⅱ grades),higher three-year survival rate(55.88%),and longer survival time than control group(all P〈0.05).Conclusion:Intraperitoneal cisplatin and docetaxel intravenous chemotherapy for advanced ovarian cancer showed good efficacy accompanied by less side effects.

关 键 词:卵巢癌 顺铂 腹腔灌注 多西紫杉醇 

分 类 号:R737.31[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象